Catalan Translation and Psychometric Validation of the QuickDASH (QuickDASH-CAT)

August 2, 2026 updated by: Ana Scott-Tennent, Corporacion Parc Tauli

Translation, Cross-cultural Adaptation and Psychometric Validation of the Catalan Version of the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH-CAT)

Patient-reported outcome measures (PROMs) are essential tools for assessing upper extremity disability from the patient's perspective and are increasingly incorporated into routine clinical practice and research. The Quick Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH) is one of the most widely used PROMs in upper limb surgery worldwide. Although the questionnaire has been translated and validated into multiple languages, no officially translated and psychometrically validated Catalan version is currently available. The aim of this study is to translate, cross-culturally adapt and psychometrically validate the Catalan version of the QuickDASH according to internationally accepted recommendations for PROM translation and validation. The project consists of two sequential phases. Phase I comprises forward translation, synthesis, back-translation, expert committee review and cognitive debriefing. Phase II consists of a prospective observational psychometric validation study in Catalan-speaking adults with upper extremity disorders. The resulting instrument is expected to become the official Catalan version of the QuickDASH for use in clinical practice and research.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

Patient-reported outcome measures (PROMs) have become an essential component of modern healthcare by providing standardized assessment of symptoms, disability and treatment outcomes directly from the patient's perspective. Their routine use has increased considerably during the last decade owing to recommendations from international scientific societies and their incorporation into both clinical research and routine outcome assessment. The Quick Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH) is among the most frequently used PROMs for evaluating upper extremity disability. Compared with the original 30-item DASH questionnaire, the abbreviated 11-item QuickDASH maintains excellent psychometric performance while substantially reducing respondent burden, facilitating its use in everyday clinical practice. Despite the widespread use of Catalan within the healthcare system in Catalonia, no officially translated and psychometrically validated Catalan version of the QuickDASH is currently available. Consequently, clinicians and researchers frequently rely on Spanish versions that may not fully reflect linguistic and cultural characteristics specific to Catalan-speaking populations. The primary objective of this study is to produce an officially translated, culturally adapted and psychometrically validated Catalan version of the QuickDASH following internationally accepted methodology and the recommendations established by the Institute for Work & Health (IWH), copyright holder of the DASH and QuickDASH questionnaires. The translation process will include two independent forward translations, synthesis of both versions, two independent back-translations, multidisciplinary expert committee review and cognitive debriefing in Catalan-speaking patients. Once the final Catalan version has been established, a prospective observational validation study will evaluate its psychometric properties in approximately 100 adult patients presenting with upper extremity disorders at Parc Taulí Hospital Universitari. Psychometric evaluation will include assessment of internal consistency, test-retest reliability, construct validity, measurement error, responsiveness and floor and ceiling effects according to internationally accepted standards for PROM validation studies. The availability of an officially validated Catalan QuickDASH is expected to facilitate standardized outcome assessment in Catalan-speaking populations, improve comparability between international studies and promote the incorporation of patient-reported outcomes into routine clinical practice.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Spain
    • Barcelona
      • Sabadell, Barcelona, Spain, 08208
        • Parc Taulí Hospital Univesritari
        • Contact:
        • Sub-Investigator:
          • Francesc Mercano Fernandez, MD
        • Sub-Investigator:
          • Jaume Camara Cabrera, PHD
        • Sub-Investigator:
          • Nona Poy, MD
        • Sub-Investigator:
          • Roger Rojas Sayol, MD
        • Sub-Investigator:
          • Joan Miquel Noguera, PHD
        • Principal Investigator:
          • Ana Scott-Tennent De Rivas, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult Catalan-speaking patients (18 years or older) presenting with an upper extremity musculoskeletal disorder (acute or chronic) at the outpatient upper extremity clinic of Parc Taulí Hospital Universitari (Sabadell, Spain), able to read and understand written Catalan and to provide written informed consent

Description

Inclusion Criteria:

  • Age 18 years or older. Native or fluent Catalan speaker. Diagnosis of an upper extremity musculoskeletal disorder requiring assessment using the QuickDASH questionnaire. Able to read and understand written Catalan. Able and willing to provide written informed consent. Able to complete the questionnaire independently.

Exclusion Criteria:

  • Cognitive impairment preventing questionnaire completion. Severe neurological or psychiatric disorders interfering with questionnaire interpretation. Inability to read or understand Catalan. Refusal or inability to provide written informed consent. Any other condition that, in the opinion of the investigator, could compromise participation or interpretation of questionnaire results.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Catalan QuickDASH Validation Cohort
Adult Catalan-speaking patients presenting with upper extremity disorders who will complete the Catalan version of the QuickDASH as part of the psychometric validation study. Participants will undergo questionnaire assessment at baseline and a subgroup will complete a second assessment for evaluation of test-retest reliability according to the study protocol.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Cross-cultural adaptation and psychometric validation of the Catalan QuickDASH
Time Frame: Baseline and completion of the translation and validation process (approximately 12 months).
Successful translation, cross-cultural adaptation and psychometric validation of the Catalan version of the Quick Disabilities of the Arm, Shoulder and Hand questionnaire following internationally accepted recommendations, including cognitive debriefing and expert committee review.
Baseline and completion of the translation and validation process (approximately 12 months).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Corporacion Parc Tauli

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Federation of European Societies for Surgery of the Hand (FESSH)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Ana Scott-Tennent De Rivas, MD, Institut d'Investigació i Innovació Parc Taulí (I3PT)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 2, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 2, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 6, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 6, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • QuickDASH-CAT-2026
  • CEIm: 2026.036-50 (Other Grant/Funding Number: FESSH PROM)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be publicly shared. Requests for access to anonymized data may be considered by the Principal Investigator and the sponsor on reasonable request, in accordance with institutional policies, ethical approval and applicable data protection regulations.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings